BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Sells $1,098,773.28 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De sold 46,896 shares of the firm’s stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $23.43, for a total transaction of $1,098,773.28. Following the sale, the chief executive officer now directly owns 414,958 shares of the company’s stock, valued at approximately $9,722,465.94. The trade was a 10.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock traded up $0.58 during trading hours on Wednesday, reaching $27.69. The company’s stock had a trading volume of 270,111 shares, compared to its average volume of 217,162. BioLife Solutions, Inc. has a one year low of $14.50 and a one year high of $28.88. The company’s 50 day simple moving average is $25.91 and its 200 day simple moving average is $24.27. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The stock has a market cap of $1.28 billion, a P/E ratio of -26.12 and a beta of 1.92.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BLFS. Craig Hallum lifted their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. KeyCorp lifted their price objective on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Benchmark reissued a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. Northland Securities upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, HC Wainwright decreased their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.43.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. boosted its position in BioLife Solutions by 4.7% during the 3rd quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock valued at $4,776,000 after purchasing an additional 8,580 shares during the period. Barclays PLC boosted its holdings in shares of BioLife Solutions by 20.1% during the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after acquiring an additional 10,803 shares during the period. Geode Capital Management LLC grew its position in shares of BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after acquiring an additional 18,473 shares during the last quarter. State Street Corp increased its holdings in shares of BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after acquiring an additional 95,788 shares during the period. Finally, Stifel Financial Corp lifted its position in BioLife Solutions by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after purchasing an additional 670 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.